Physician profile
Faten Abdullah
NPI 1467718049
$5,538.60
in general payments reported to CMS, 2019-2025
30 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $503 · 2021: $325 · 2022: $202 · 2023: $205 · 2024: $885 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,433.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $961.78 | 2019-2022 | |
| Lilly USA, LLC | $497.76 | 2019-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $363.60 | 2024 | Voquezna |
| Pfizer INC. | $315.73 | 2019-2025 | |
| Eisai INC. | $298.54 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $288.92 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $187.88 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.55 | 2021-2025 | |
| Astellas Pharma US INC | $143.24 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $135.62 | 2024 | Aptima |
| Alkermes, INC. | $99.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.18 | 2019-2021 | |
| Amgen INC. | $86.67 | 2020-2025 | Repatha, Otezla |
| Dexcom, INC. | $69.71 | 2023 | Dexcom G7 Gss (161) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $65.08 | 2022 | |
| Sunovion Pharmaceuticals INC. | $63.33 | 2019 | |
| Abbvie INC. | $57.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.93 | 2021 | |
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Genentech USA, INC. | $22.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.82 | 2021 | |
| Dynavax Technologies Corporation | $18.34 | 2025 | Heplisav-B |
| Abbott Laboratories | $15.85 | 2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $15.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.44 | 2022 | |
| Inogen, INC. | $12.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.27 | 2021 | |
| Merck Sharp & Dohme LLC | $11.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faten Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.